Clinical Trial Update: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) [Phase 3]

View source ↗

Summary

Phase 3 trial update for VGX-3100 with electroporation in cervical HSIL/Cervical dysplasia completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Dysplasia
• Cervical High-grade Squamous Intraepithelial Lesion

Drugs mentioned

• VGX-3100

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Status: COMPLETED | Results posted: 2023-07-25